— Oveporexton treats more than symptoms, restores orexin signaling
by Nicole Lou, Senior Staff Writer, MedPage Today
August 6, 2026
• 2 min read
The FDA approved oveporexton (Orzeyful) for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults, the agency announced Wednesday.
Oveporexton is a first-in-class orexin treatment that goes beyond symptom relief alone and targets the root cause of the rare sleep disorder.
“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it,” said Tiffany Farchione, MD, director of the division of psychiatry within the FDA’s Center for Drug Evaluation and Research, in a statement. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.”
Narcolepsy type 1 is a chronic neurologic disease caused by a loss of brain cells that produce orexin, a neuropeptide that helps regulate wakefulness, sleep, and muscle tone. Affected individuals tend to have round-the-clock symptoms, namely excessive daytime sleepiness, cataplexy, cognitive symptoms, and disrupted nighttime sleep. Narcolepsy type 1 affects an estimated one in 2,000 people in the U.S.
Oveporexton is an oral orexin receptor 2 agonist that restores the missing orexin signaling in narcolepsy type 1. The medicine is a tablet taken twice daily.
“Until now, people have managed narcolepsy type 1 with treatments that target symptom relief,” said Emmanuel Mignot, MD, PhD, principal U.S. investigator in the phase III program, in a press release from drugmaker Takeda. “As the first and only approved orexin therapy to treat the broad spectrum of the disease, Orzeyful can enable a different kind of conversation in the doctor’s office about treatment options.”
Two phase III randomized, double-blind trials formed the basis of oveporexton’s approval: FirstLight and RadiantLight.
Across the two 12-week studies, counting 273 adults with narcolepsy type 1, oveporexton 2 mg twice daily normalized wakefulness, with recipients reporting less daytime sleepiness, a significant reduction in cataplexy episodes, and meaningful improvement across the spectrum of narcolepsy symptoms (e.g., sleep paralysis, hallucinations, disrupted nighttime sleep).
Common treatment-emergent adverse events included insomnia, as well as urinary urgency and frequency — in line with the drug’s mechanism of action. Also reported were nasopharyngitis events and excessive saliva. None of these events were severe enough to merit medical attention.
Of note, however, asymptomatic creatine phosphokinase (CPK) elevations greater than five times the upper limit of normal were observed in 11% of oveporexton-treated patients versus 5% of patients in placebo groups. Two of these cases were characterized by markedly elevated CPK and transaminase levels; both patients discontinued treatment. None of the cases were associated with myoglobinuria or renal impairment.
Even so, patients are advised to report unexplained muscle pain, weakness, or dark urine, particularly when engaging in vigorous physical activity or taking concomitant drugs associated with myotoxicity.
Additionally, oveporexton is contraindicated in patients taking strong CYP3A inhibitors.
Oveporexton will not be available until a scheduling decision is issued by the Drug Enforcement Agency, expected within 90 days. After the controlled substance classification is determined, the medication will be sold through a specialty pharmacy.
